Affordable Access

Access to the full text

CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy

Authors
  • Miri, Seyed Mohammad1
  • Tafsiri, Elham2
  • Cho, William Chi Shing3
  • Ghaemi, Amir4
  • 1 Sharif University of Technology, Tehran, Iran , Tehran (Iran)
  • 2 Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran , Tehran (Iran)
  • 3 Queen Elizabeth Hospital, Hong Kong, China , Hong Kong (China)
  • 4 Pasteur Institute of Iran, Tehran, Iran , Tehran (Iran)
Type
Published Article
Journal
Cancer Cell International
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Sep 15, 2020
Volume
20
Issue
1
Identifiers
DOI: 10.1186/s12935-020-01546-8
Source
Springer Nature
Keywords
License
Green

Abstract

Cancer immunotherapy has been emerged as a promising strategy for treatment of a broad spectrum of malignancies ranging from hematological to solid tumors. One of the principal approaches of cancer immunotherapy is transfer of natural or engineered tumor-specific T-cells into patients, a so called “adoptive cell transfer”, or ACT, process. Construction of allogeneic T-cells is dependent on the employment of a gene-editing tool to modify donor-extracted T-cells and prepare them to specifically act against tumor cells with enhanced function and durability and least side-effects. In this context, CRISPR technology can be used to produce universal T-cells, equipped with recombinant T cell receptor (TCR) or chimeric antigen receptor (CAR), through multiplex genome engineering using Cas nucleases. The robust potential of CRISPR-Cas in preparing the building blocks of ACT immunotherapy has broaden the application of such therapies and some of them have gotten FDA approvals. Here, we have collected the last investigations in the field of immuno-oncology conducted in partnership with CRISPR technology. In addition, studies that have addressed the challenges in the path of CRISPR-mediated cancer immunotherapy, as well as pre-treatment applications of CRISPR-Cas have been mentioned in detail.

Report this publication

Statistics

Seen <100 times